Amgen Inc. $AMGN Stock Holdings Lowered by Pacer Advisors Inc.

Pacer Advisors Inc. lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,613,121 shares of the medical research company’s stock after selling 155,180 shares during the period. Amgen makes up approximately 1.1% of Pacer Advisors Inc.’s portfolio, making the stock its 9th largest position. Pacer Advisors Inc.’s holdings in Amgen were worth $455,223,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in AMGN. Brighton Jones LLC raised its stake in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Ieq Capital LLC raised its position in Amgen by 43.8% in the 1st quarter. Ieq Capital LLC now owns 51,541 shares of the medical research company’s stock worth $16,058,000 after buying an additional 15,711 shares during the last quarter. CreativeOne Wealth LLC lifted its stake in Amgen by 12.2% during the 1st quarter. CreativeOne Wealth LLC now owns 14,738 shares of the medical research company’s stock valued at $4,592,000 after acquiring an additional 1,606 shares during the period. Wealth Preservation Advisors LLC purchased a new stake in shares of Amgen during the 1st quarter valued at about $25,000. Finally, Truvestments Capital LLC grew its stake in shares of Amgen by 39.7% in the first quarter. Truvestments Capital LLC now owns 1,105 shares of the medical research company’s stock worth $344,000 after acquiring an additional 314 shares during the period. 76.50% of the stock is owned by institutional investors.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the sale, the executive vice president owned 41,923 shares in the company, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 10,908 shares of company stock valued at $3,674,966. Corporate insiders own 0.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on AMGN shares. Wells Fargo & Company increased their price objective on shares of Amgen from $300.00 to $325.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. Citigroup increased their price target on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a report on Wednesday, September 24th. BMO Capital Markets lifted their price objective on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. The Goldman Sachs Group reiterated a “buy” rating on shares of Amgen in a research report on Tuesday, November 25th. Finally, Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Amgen has a consensus rating of “Moderate Buy” and a consensus target price of $332.85.

Amgen Stock Performance

NASDAQ AMGN opened at $332.50 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. Amgen Inc. has a twelve month low of $257.05 and a twelve month high of $346.38. The business has a 50-day moving average price of $322.29 and a 200-day moving average price of $301.33. The firm has a market cap of $179.04 billion, a price-to-earnings ratio of 25.70, a price-to-earnings-growth ratio of 3.10 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. During the same period in the previous year, the firm earned $5.58 EPS. The firm’s revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is currently 73.57%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.